News

Dyne Therapeutics - Emergence As A Superior DM1 / DMD Player Warrants Rating Upgrade
I am upgrading Dyne Therapeutics stock to a 'Buy' rating due to promising late-stage DM1 and DMD drug candidates and ...
U.S. judge upholds FDA's removal of Ozempic, Wegovy from drug shortage list
A federal judge in Texas has upheld the U.S. Food and Drug Administration's decision to remove Novo Nordisk's blockbuster ...